JPET #113084 5 result in a low incidence of extrapyramidal side-effects (Ichikawa and Meltzer, 1999; Rollema et al., 2000) . Furthermore, treatment with clozapine selectively increased dopamine release in the rat prefrontal cortex and ventral hippocampus, an effect at least partially mediated by 5-HT 1A receptors (Chung et al., 2004) , potentially inhibiting serotonergic transmission via activation of 5-HT 1A autoreceptors (Bantick et al., 2001) .
Several other of the proposed beneficial 5-HT 1A receptor components of antipsychotic drug action have been deduced from indirect and in vitro studies, such as in binding assays or cell cultures (Newman-Tancredi et al., 2005; Bruins Slot et al., 2006) . Importantly, however, these atypical antipsychotics tend to have a rich pharmacology, including affinity for dopamine (e.g. D 2 ), 5-HT (e.g. 5-HT 1A , 5-HT 2A ) and several other receptor sub-types, the combination of which is likely to be responsible for their clinical efficacy. Therefore, the specific importance of 5-HT 1A receptor agonist or antagonist properties in the antipsychotic profile of these drugs in vivo remains unclear.
In contrast to possible beneficial actions of 5-HT 1A receptor activation (see above), some of these effects resemble a schizophrenia-like state, rather than an antipsychotic action.
For example, it is well described that administration of the prototypical 5-HT 1A receptor agonist, 8-hydroxy-di-propylaminotetralin (8-OH-DPAT) causes a disruption of prepulse inhibition (PPI) (Rigdon and Weatherspoon, 1992; Sipes and Geyer, 1995; Gogos and Van den Buuse, 2004) , a measure of sensorimotor gating which is also deficient in schizophrenia (Braff and Geyer, 1989; . The effect of 8-OH-DPAT on PPI could be blocked by pretreatment with the selective 5-HT 1A receptor antagonist, (+)WAY 100, 135 (N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenyl-propanamide) (Sipes and Geyer, 1995; Czyrak et al., 2003) , confirming that this disruption is mediated by stimulation of 5-HT 1A receptors rather than 5-HT 7 receptors for which 8-OH-DPAT also has affinity (Shen et This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on April 1, 2017 jpet.aspetjournals.org Downloaded from JPET #113084 6 al., 1993) . However, there is limited information on the effect of antipsychotic drugs on 5-HT 1A receptor mediated disruptions of PPI. Therefore the aim of the present study was to compare six antipsychotic drugs, haloperidol, risperidone, clozapine, olanzapine, amisulpride and aripiprazole with respect to their ability to modulate the action of 8-OH-DPAT on PPI.
We also tested the dopamine D 2 receptor antagonist, raclopride, as comparison for haloperidol, and the 5-HT 1A receptor partial agonists, MDL 73,005EF (8-[2-(2,3-dihydro-1,4-benzodioxin-2-yl-methylamino)ethyl]-8-azaspiro [4, 5] decane-7,9-dione methyl sulphonate) and buspirone.
We measured startle amplitude, as well as PPI at a short interstimulus interval (ISI, 30 msec) 
Animals
Experiments were done on male Sprague-Dawley rats (body weight 300-400 g) which were obtained from the breeding colony at the Department of Pathology, University of Melbourne. After arriving at the institute, the rats were allowed at least one week of acclimation before testing commenced.
Protocol
Around 2-3 days before the start of the experiments, all rats were acclimated to the PPI procedure once without any treatments. After this 'pre-test', rats received two treatments per test (pretreatment with antipsychotic drug or saline vs. treatment with 8-OH-DPAT or saline) and were tested six times with 3-4 day intervals: saline/saline, antipsychotic drug low dose/saline, antipsychotic drug high dose/saline, saline/8-OH-DPAT, antipsychotic drug low dose/8-OH-DPAT, antipsychotic drug high dose/8-OH-DPAT. One separate cohort of 7-11 rats was used for each antipsychotic drug, except MDL 73,005EF and buspirone, which were tested at only one dose and were combined in one experiment. The sequence of treatment was pseudo-randomized so that at the end of the series of experiments, all rats in a cohort had received all treatment combinations. Injection volumes were 1 ml/kg body weight.
Antipsychotic drugs or saline were injected intraperitoneally (i.p.) 30 min before injection of 0.5 mg/kg of 8-OH-DPAT or saline, which was injected subcutaneously (s.c.) about 5 min before the animals were placed in the PPI enclosures.
This article has not been copyedited and formatted. The final version may differ from this version. containing 400 mg amisulpride each, which were dissolved in saline to obtain the required doses of 10 mg/kg or 50 mg/kg. For pretreatment with aripiprazole (7-[4-[-4[-(2,3-dichlorophenyl Combined analysis of startle data for both haloperidol doses revealed a trend for a main effect of Dose (F(2,12)=2.9, P=0.089). Compared to saline, haloperidol at 0.25 mg/kg, but not 0.05 mg/kg, significantly reduced startle amplitudes (F(1,6)=15.9; P=0.007). 8-OH-DPAT treatment tended to cause an increase in startle responses, however this effect was not significant (Table 1) .
While haloperidol had no effect on PPI at the 30 msec interval, there were significant main effects of 8-OH-DPAT treatment (F(1,6)=31.0, P=0.001) and of prepulse level (F(3,18)=125.0, P<0.001). However, there were no significant treatment effects at any of the individual prepulse intensities (Fig. 1 ).
Combined analysis of all haloperidol doses and all prepulse levels at the 100 msec interval showed significant main effects of Dose (F(2,10)=17.7, P=0.001), 8-OH-DPAT (F(1,5)=35.0, P=0.002) and Prepulse (F(3,15)=113.0, P<0.001). At PP2, the disruption of PPI by 8-OH-DPAT was significant after pretreatment with saline and 0.05 mg/kg of haloperidol, but was blocked after pretreatment with 0.25 mg/kg of haloperidol ( Fig. 1 ). At PP4, the effect of 8-OH-DPAT was significant after pretreatment with 0.05 mg/kg of haloperidol, although not after saline pretreatment, and again was blocked after pretreatment with 0.25 mg/kg of haloperidol ( Fig. 1) . Similarly, at PP8 and PP16, the effect of 8-OH-DPAT was significant after pretreatment with saline and 0.05 mg/kg of haloperidol and was blocked after pretreatment with 0.25 mg/kg of haloperidol ( Fig. 1 ). At none of the prepulse intensities did haloperidol treatment significantly alter PPI on its own.
This article has not been copyedited and formatted. The final version may differ from this version. To confirm and extend the observation, that haloperidol pretreatment could block the action of 8-OH-DPAT on PPI, we also tested raclopride, another (putative) antipsychotic drug with a predominantly dopamine D 2 blocking mode of action.
Analysis of startle data showed that neither raclopride nor 8-OH-DPAT significantly affected startle (Table 1 ) although 8-OH-DPAT treatment tended to cause an increase in startle responses. Raclopride had no effect on PPI at the 30 msec interval, although there was a significant main effect of Prepulse level (F(3,18)=110.4, P<0.001). As with haloperidol, there were no significant treatment effects at any of the individual prepulse intensities (Fig. 2 ).
Combined analysis of all raclopride doses and all prepulse levels at the 100 msec interval showed significant main effects of 8-OH-DPAT (F(1,6)=30.3, P=0.002) and Prepulse (F(3,18)=52.2, P<0.001). In this cohort of rats, there were no treatment effects at PP2 (Fig. 2 ).
Similar to the haloperidol experiment, at PP4 the disruption of PPI by 8-OH-DPAT was significant after pretreatment with 0.05 mg/kg of raclopride, although not after saline pretreatment, and was blocked after pretreatment with 0.25 mg/kg of raclopride ( Fig. 2 ). At PP8, the effect of 8-OH-DPAT was significant after pretreatment with saline and 0.05 mg/kg of raclopride and was blocked after pretreatment with 0.25 mg/kg of raclopride ( Fig. 2 ). At PP16, the effect of 8-OH-DPAT was significant only after saline pretreatment. At none of the prepulse intensities did raclopride pretreatment significantly alter PPI on its own.
Clozapine (Fig. 3, Table 1)
To assess if the blocking action of haloperidol and raclopride extended to atypical
antipsychotic drugs, we also tested clozapine, olanzapine, risperidone, amisulpride and aripiprazole.
This article has not been copyedited and formatted. The final version may differ from this version. Thus, average PPI after saline-or 8-OH-DPAT treatment was 22±9% and 32±3%, respectively, after saline pretreatment, compared to -1±11% and 30±4%, respectively, after clozapine pretreatment. At PP2, there was no effect of 8-OH-DPAT after saline or 1 mg/kg of clozapine pretreatment, however after 5 mg/kg of clozapine, PPI tended to be reduced (P=0.072) revealing a significant PPI enhancing effect of 8-OH-DPAT (Fig. 3) . At PP4, PPI was significantly reduced by 5 mg/kg of clozapine, again allowing a significant effect of 8-OH-DPAT (Fig. 3) . At PP8, the effect of 5 mg/kg of clozapine was not significant, although again an apparent effect of 8-OH-DPAT appeared after this dose of the antipsychotic (Fig. 3 ).
At PP16, there were no significant treatment effects, although the difference between 8-OH-DPAT after saline pretreatment and after 5 mg/kg of clozapine pretreatment reached trend level (P=0.070) (Fig. 3) .
The effect of clozapine on PPI at the 100 msec ISI did not show the same reducing influence as seen at the 30 msec ISI, however there was a Dose x 8-OH-DPAT x Prepulse interaction (F(6,48)=2.8, P=0.020) again suggesting complex interacting effects of clozapine This article has not been copyedited and formatted. The final version may differ from this version. .001). At PP2, the significant effect of 8-OH-DPAT was blocked by both the 1 and 5 mg/kg dose. On the other hand, no effect of clozapine at either dose was observed at PP4, while at PP8 and PP16, both doses appeared to enhance the effect of 8-OH-DPAT (Fig. 3) .
Olanzapine (Fig. 4, Table 1)
Olanzapine significantly reduced startle responses (F(2,14)=5.1, P=0.021) at the 5 mg/kg dose (F(1,7)=43.6; P<0.001) but not the 1 mg/kg dose. 8-OH-DPAT treatment tended to cause an increase in startle amplitude, an effect which became significant when data for saline and 5 mg/kg of olanzapine were analyzed (F(1,7)=8.1, P=0.025) ( Table 1) .
PPI at the 30 msec ISI showed the expected effect of Prepulse intensity (F(3,21)=102.6, P<0.001) but was not significantly affected by either olanzapine or 8-OH-DPAT (Fig. 4) .
PPI at the 100 msec ISI again showed the expected effect of Prepulse intensity (F(3,21)=101.5, P<0.001) and was significantly reduced by 8-OH-DPAT treatment (F(1,7)=43.2, P<0.001). In addition, there was a main effect of olanzapine of borderline significance (F(2,14)=3.8, P=0.048). At none of the prepulse intensities did olanzapine block the reducing effect of 8-OH-DPAT (Fig. 4) . Thus, the effect of 8-OH-DPAT was significant at all prepulse intensities and all pretreatments, except after 1 mg/kg of olanzapine at PP2 and 5 mg/kg of olanzapine at PP8, which failed to reach significance (Fig. 4) . At none of the prepulse intensities did olanzapine pretreatment significantly alter PPI on its own.
This article has not been copyedited and formatted. The final version may differ from this version. This was particularly clear at PP2, where 1 mg/kg of risperidone significantly reduced PPI on its own, unmasking significant enhancement of PPI by 8-OH-DPAT (Fig. 5) . At other prepulse intensities, neither risperidone or 8-OH-DPAT affected PPI at the 30 msec ISI (Fig. 5) .
Analysis of PPI at the 100 msec ISI revealed a main effect of risperidone dose (F(2,12)=11.7, P=0.002), reflecting a general tendency for PPI to be enhanced after risperidone treatment (Fig. 5 ). In addition, there was the expected disruption of PPI by 8-OH-DPAT (F(1,6)=36.7, P=0.001) and main effect of prepulse intensity (F(3,18)=93.2, P<0.001).
At PP2, PP8 and PP16, 1 mg/kg of risperidone significantly increased PPI on its own while generally not blocking the disruption induced by 8-OH-DPAT (Fig. 5) . Thus, the effect of 8-OH-DPAT was significant at all prepulse intensities and all pretreatment doses, except after 0.2 mg/kg of risperidone at PP2, after 1 mg/kg of risperidone at PP4 (P=0.069), and after saline pretreatment at PP8 and PP16 (Fig. 5 ).
This article has not been copyedited and formatted. The final version may differ from this version. Amisulpride had no effect on startle amplitude (Table 1) , while 8-OH-DPAT significantly increased startle (F(1,9)=13.6, P=0.005).
Analysis of PPI at the 30 msec ISI showed the expected main effect of Prepulse intensity (F(3,27)=48.8, P<0.001). 8-OH-DPAT treatment tended to increase PPI, but only at lower prepulse intensities (8-OH-DPAT x Prepulse interaction F(3,27)=6.5, P=0.002).
However, analysis of individual prepulse intensities did not reveal any significant effects of 8-OH-DPAT or amisulpride (Fig. 6 ).
Analysis of PPI at the 100 msec ISI revealed marked disruption by 8-OH-DPAT (F(1,9)=60.6, P<0.001) and a main effect of prepulse intensity (F(3,27)=93.1, P<0.001),
however there was no effect of amisulpride (Fig. 6) . As with clozapine, olanzapine and risperidone, amisulpride pretreatment did not block the action of 8-OH-DPAT on PPI (Fig. 6) .
Thus, the effect of 8-OH-DPAT was significant at all prepulse intensities and all pretreatment doses, except after 10 mg/kg of amisulpride at PP4 (P=0.079), PP8 and at PP16 (Fig. 6 ). At none of the prepulse intensities did amisulpride pretreatment significantly alter PPI on its own.
Aripiprazole (Fig. 7 , Table 1) 8-OH-DPAT significantly enhanced startle amplitude (F(1,7)=9.0; P=0.020), however there were no effects of aripiprazole pretreatment (Table 1) . PPI at the 30 msec ISI showed the main effect of Prepulse intensity (F(3,21)=78.8, P<0.001) but was not significantly affected by either aripiprazole or 8-OH-DPAT (Fig. 7) .
Analysis of PPI data at the 100 msec ISI revealed a significant disruption by 8-OH-DPAT treatment (F(1,7)=25.4; P<0.001) and a main effect of prepulse intensity This article has not been copyedited and formatted. The final version may differ from this version. animals which were pretreated with 5 mg/kg of aripiprazole, however these differences did not reach statistical significance (Fig. 7) . In contrast, at PP4, 8-OH-DPAT significantly disrupted PPI and this effect was blocked by 5 mg/kg of aripiprazole (Fig. 7) . Also at PP8 and PP16, 8-OH-DPAT significantly disrupted PPI, however this was not influenced by aripiprazole pretreatment (Fig. 7) .
MDL 73,005EF and buspirone (Fig. 8, Table 1)
There were no significant main effects of MDL 73,005EF on startle amplitude (Table   1 ). PPI at the 30 msec ISI was slightly, but significantly increased by MDL 73,005EF treatment (F(1,16)=5.7, P=0.030) in addition to the main effect of prepulse intensity (F(3,48)=114.0, P<0.001) (Fig. 8) . At PP2, 8-OH-DPAT significantly increased PPI, an effect which was not observed after pretreatment with MDL 73,005EF because of a significant increase in PPI induced by this pretreatment itself (Fig. 8) . At PP4, a similar increase of PPI by MDL 73,005EF pretreatment was seen which was close to significance (P=0.065). At PP16, but not at PP8, there was again a slight, but significant increase of PPI after MDL 73,005EF pretreatment. 8-OH-DPAT had no significant effects at PP4, PP8 or PP16 (Fig. 8) .
At the 100 msec ISI, again there was a main effect of prepulse intensity (F(3,48)=96.4, P<0.001) and the expected marked disruption of PPI by 8-OH-DPAT treatment (F(1,16)=14.8, P=0.001). There was also an overall increase in PPI induced by MDL 73,005EF pretreatment (F(1,16)=10.3, P=0.006) but no statistical interaction between the effects of MDL 73,005EF pretreatment and 8-OH-DPAT treatment (Fig. 8) (Fig. 8) although the effects only reached trend level (P=0.091 and P=0.077, respectively). At PP16, PPI was slightly, but significantly lower after 8-OH-DPAT treatment in saline controls only (Fig. 8) .
Pretreatment with 5 mg/kg of buspirone did not significantly alter startle amplitude (Fig. 8) . Neither buspirone pretreatment nor 8-OH-DPAT significantly affected PPI at the 30 msec ISI (Fig. 8) and only a main effect of prepulse intensity was observed (F(3,48)=155.7, P<0.001). On the other hand, analysis of PPI at the 100 msec ISI revealed main effects of prepulse intensity F(3,48)=91.6, P<0.001), buspirone pretreatment (F(1,16)=6.7, P=0.020),
and of 8-OH-DPAT treatment (F(1,16)=4.2, P=0.057). There was also a significant interaction of buspirone pretreatment with the effect of 8-OH-DPAT (F(1,16)=7.1, P=0.017), reflecting blockade of the effect of 8-OH-DPAT treatment in buspirone-pretreated rats (Fig. 8) . Thus, while buspirone pretreatment did not affect PPI on its own, it blocked the disruption of PPI by subsequent 8-OH-DPAT treatment at all prepulse intensities (Fig. 8 ).
This article has not been copyedited and formatted. The final version may differ from this version. (Braff and Geyer, 1989; . (Berendsen et al., 1990) . This complicates the explanation of the action of antipsychotic drugs on the effect of 8-OH-DPAT. Aripiprazole is reported to have an affinity for dopamine D 2 receptors only slightly lower than haloperidol (pKi = 8.59 vs. 9.01, respectively) (Newman-Tancredi et al., 2005) . Aripiprazole is a partial agonist at these receptors (Burris et al., 2002; Shapiro et al., 2003) while in rats it is metabolized in vivo to a full D 2 receptor antagonist (Wood et al., 2006) . Thus the effect of aripiprazole could be explained by its blocking action on dopamine D 2 receptors as well as or rather than an action on 5-HT 1A receptors. Even the effect of buspirone in blocking the 8-OH-DPAT induced disruption of PPI could have been mediated by its binding to dopamine D 2 receptors. Buspirone displays high affinity for these receptors and has been shown to act as a dopamine D 2 receptor antagonist in several behavioral models (Ryan et al., 1993; Protais et al., 1998 statistical interaction of risperidone pretreatement with the disruption of PPI caused by 8-OH-DPAT treatment. This lack of interaction was mainly caused by an increase in resting PPI after risperidone pretreatment and it should be noted that PPI in animals treated with both risperidone and 8-OH-DPAT was similar to that in controls, which would further support the conclusion that dopamine D 2 receptor blockade is able to inhibit the effect of 5-HT 1A receptor activation on PPI.
In a recent study, several antipsychotics were tested against the disruption of PPI induced by treatment with the dopamine receptor agonist, apomorphine (Auclair et al., 2006) .
Of the antipsychotics we also included, pretreatment with haloperidol, risperidone and olanzapine blocked the effect of apomorphine, while clozapine and aripiprazole were less effective (Auclair et al., 2006) . Interestingly, when pretreatment with mixed D 2 /5-HT 1A
ligands was combined with a 5-HT 1A receptor antagonist, the ability to block the action of apomorphine was enhanced. These results support our finding of a functional interaction of activation of D 2 and 5-HT 1A receptors in PPI regulation, but also emphasize the complexity of this interaction. It would be reasonable to assume that involvement of dopamine D 2 receptors in PPI is modulated both positively and negatively by 5-HT 1A receptor activation. Further experimentation, for example with local injections into the brain, is needed to elucidate such interactions.
Our experiments also showed effects of antipsychotic drugs by themselves. For example, olanzapine and risperidone pretreatement increased PPI at the 100 msec ISI, whereas clozapine and risperidone induced complex, prepulse-dependent effects at the 30 msec ISI.
These results show that for the full interpretation of drug effects on PPI, an extended protocol, (Plappert et al., 2004; Swerdlow et al., 2004a; Swerdlow et al., 2004b) . The regulation and functional significance of PPF is poorly understood. Men have been shown to display higher PPI than women, but women displayed higher PPF than men (Aasen et al., 2005) . PPF was found to be reduced in patients with schizophrenia and their unaffected siblings (Wynn et al., 2004) . Thus, the modulatory effects of antipsychotic drugs on PPF seen in the current study could have relevance for our understanding of the mechanism of action of these drugs in patients with schizophrenia. PPI at longer ISIs is susceptible to attentional mechanisms, whereas PPI at shorter ISIs is a more "automatic" mechanism (Filion et al., 1993; Bohmelt et al., 1999) and these components could be differentially affected in schizophrenia and by antipsychotic drugs. Thus, psychopharmacological effects on PPI need to be interpreted with caution as the results may represent multiple and separate startle modulation mechanisms. In our experiments, 8-OH-DPAT only disrupted PPI at the 100 msec ISI, making it likely that only PPI, not PPF mechanisms, are involved.
PPI reflects a gating mechanism for sensory information and, as such, could be involved in some of the cognitive deficits seen in patients with schizophrenia (Braff and Geyer, 1989; . Antipsychotic drugs have been shown by some studies to reverse the disruption of PPI seen in patients with schizophrenia. For example, treatment with either olanzapine or amisulpride reversed PPI deficits in patients with schizophrenia (Quednow et al., 2006) . Treatment with clozapine (Oranje et al., 2002) and risperidone similarly restored PPI deficits. In contrast, other studies have not found a reversal with antipsychotic treatment, for example treatment with risperidone (Mackeprang et al., 2002; Oranje et al., 2002) or haloperidol or olanzapine (Duncan et al., 2003) . As the cause of PPI deficits in schizophrenia is unknown, the mechanism by which antipsychotic drugs potentially modulate this deficit, remains unclear. Therefore in the present This article has not been copyedited and formatted. The final version may differ from this version. (Koch, 1999; Geyer et al., 2001) 
